{"id":"46c0311a-598f-5941-88dd-639b85173698","stable_key":"1fb6218a-60d1-55ea-87fe-07d15d0fc46f:atorvastatin-c-reactive-protein","predicate":"reduces","statement":"Atorvastatin significantly reduced high-sensitivity C-reactive protein alongside the reduction in cholesterol.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"50e108f0-1b9c-5040-afbb-670187ab987d","mechanism_event_label":"Atorvastatin significantly reduced high-sensitivity C-reactive protein alongside the reduction in cholesterol.","subject":{"id":"64f4b2c7-afdf-5b9a-b6f9-015a7aa96eee","slug":"atorvastatin","display_name":"Atorvastatin","entity_type_key":"small_molecule"},"object":{"id":"ea0a3d14-17b9-5f68-98d1-07b246c42c6d","slug":"serum-crp-concentration","display_name":"Serum C-reactive protein concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"50e108f0-1b9c-5040-afbb-670187ab987d","stable_key":"1fb6218a-60d1-55ea-87fe-07d15d0fc46f:atorvastatin-c-reactive-protein-event","event_type":"observed_relationship","label":"Atorvastatin significantly reduced high-sensitivity C-reactive protein alongside the reduction in cholesterol.","description":"Atorvastatin significantly reduced high-sensitivity C-reactive protein alongside the reduction in cholesterol.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"64f4b2c7-afdf-5b9a-b6f9-015a7aa96eee","slug":"atorvastatin","display_name":"Atorvastatin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"ea0a3d14-17b9-5f68-98d1-07b246c42c6d","slug":"serum-crp-concentration","display_name":"Serum C-reactive protein concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"ac5f5914-4824-5f9b-93c7-a6b5a52b53af","slug":"ldl-cholesterol-concentration","display_name":"LDL cholesterol concentration","entity_type_key":"cellular_process"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"16 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"84 Japanese type 2 diabetic patients with hypercholesterolaemia","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Atorvastatin for 16 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"An inflammatory marker falling alongside cholesterol in an open-label study does not separate an effect on inflammation from an effect of lower lipids.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"84 Japanese type 2 diabetic patients with hypercholesterolaemia","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Atorvastatin significantly reduced high-sensitivity C-reactive protein alongside the reduction in cholesterol.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. (2006). https://pubmed.ncbi.nlm.nih.gov/16324921/ DOI: 10.1016/j.metabol.2005.07.017","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"High-sensitivity C-reactive protein, with plasminogen activator inhibitor 1, monocyte chemotactic protein 1 and interleukin 6 also measured","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3022629d-0bb1-5cc3-92fc-b2c88fb33705","evidence_kind":"source_excerpt","locator":"Lines 45-54","start_line":45,"end_line":54,"excerpt":"## atorvastatin-c-reactive-protein\nAtorvastatin significantly reduced high-sensitivity C-reactive protein alongside the reduction in cholesterol.\nModel/species: 84 Japanese type 2 diabetic patients with hypercholesterolaemia\nTissue/system: High-sensitivity C-reactive protein, with plasminogen activator inhibitor 1, monocyte chemotactic protein 1 and interleukin 6 also measured\nExposure: Atorvastatin for 16 weeks\nRoute: Oral\nDuration: 16 weeks\nLimits: An inflammatory marker falling alongside cholesterol in an open-label study does not separate an effect on inflammation from an effect of lower lipids.\nPrimary reference: Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. (2006). https://pubmed.ncbi.nlm.nih.gov/16324921/ DOI: 10.1016/j.metabol.2005.07.017\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a4431d8c-34d7-5db7-9edf-a35f68feba39","stable_key":"import-1fb6218a-60d1-55ea-87fe-07d15d0fc46f","title":"Atorvastatin: mechanism of action from target occupancy to isoprenoids, transport, muscle and metabolism (2026-09-22)","document_type":"imported_text","citation_label":"Original AI-assisted curation of twelve primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Findings obtained with mevastatin, simvastatin or the statin class are recorded against those subjects. Study-specific citations, doses, negative findings and limitations retained. Not publisher full text.","file_path":"","sha256":"6307f1acf99f90662320328974781ee660348754257b1e1555701ad597edc8e5","revision_id":"447c5978-ba3f-58fe-ac85-664caa72e01b","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}